专蛋白的变化预测了阿达利木马布治疗性结肠炎的失败
Natsuki Ishida1, Kenichi Takahashi2, Yusuke Asai2
1Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
PloS one
|January 2, 2024
概括
在治疗早期测量血清白蛋白水平的简单血液测试可以预测阿达利木马布是否对性结肠炎有效. 2周/0周的白蛋白比为1.00或更低,表明可能在六个月内治疗失败.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗瘤坏死因子 (TNF) -α抗体是性结肠炎 (UC) 的关键疗法.
- 阿达利穆马布 (ADA) 是一种广泛用于治疗UC的抗TNF-α生物药物.
- 早期预测ADA的治疗效果对于优化UC管理至关重要.
研究的目的:
- 评估血清白蛋白 (Alb) 变化作为UC患者ADA治疗的预后因素.
- 在性结肠炎中识别ADA治疗失败的早期指标.
主要方法:
- 对34名接受ADA治疗的UC患者的回顾性分析.
- 在治疗失败和非失败组之间比较生物数据,包括血清白蛋白.
- 接收器运行特征 (ROC) 曲线分析,以确定第2周/第0周 Alb 比率的预测值.
主要成果:
- 在失败和非失败组之间的2周/0周Alb比率中观察到显著差异.
- 在ROC分析中,发现ADA失败预测的2周/0周Alb比率截止值为1.00 (AUC=0.868).
- 在临床活跃的患者中,一周2/周0 Alb比率≤1.00预测ADA在6个月内失败.
结论:
- 2周/0周血清白蛋白比为UC中ADA治疗的有价值的早期预后标志物.
- 一周2/周0 Alb比值为1.00或更低,表明治疗失败的可能性很高,用于UC的ADA治疗.
- 这一发现可能有助于及时调整接受ADA的性结肠炎患者的治疗.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
144
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
144
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
140
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
140
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Inflammatory Bowel Disease I: Ulcerative Colitis
187
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
187
Renal Failure: Dose Adjustments
94
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
94


